{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280235","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.394631+00:00","generated_at":"2026-05-16T20:29:34.294960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aardvark Therapeutics Q3 net loss $16.3M; cash $126.4M; FDA expands PWS trial age to 10 years","bullets":["Cash, equivalents, and short-term investments of $126.4M as of Sep 30, 2025; expected to fund operations into 2027.","Net loss of $16.3M for Q3 2025 vs $4.2M for Q3 2024, driven by increased R&D and G&A expenses.","R&D expenses $13.7M (vs $4.1M) and G&A expenses $4.0M (vs $1.0M) due to ARD-101 development and public company costs.","FDA agreed to reduce minimum age for HERO Phase 3 trial (ARD-101 for PWS) from 13 to 10 years, broadening eligibility.","Preclinical ARD-201 data showed preserved lean mass, glucose control vs tirzepatide, and weight management post-GLP-1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280235","json":"https://secwatch.observer/filing/0001193125-25-280235.json","markdown":"https://secwatch.observer/filing/0001193125-25-280235.md","text":"https://secwatch.observer/filing/0001193125-25-280235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525280235/0001193125-25-280235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312525280235/ck0001774857-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:29:34.294960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}